RESUMEN
Herein we report that a preferable inhibition of the nucleation phase of Aß42, related to the formation of toxic oligomers, by triterpenoids from medicinal herbs originates from a salt bridge of their carboxy groups with Lys16 and 28 in Aß42. Such a direct interaction targeting the monomer, dimer, and trimer suppressed further oligomerization. In contrast, the corresponding congeners without carboxy groups failed to do so.
Asunto(s)
Péptidos beta-Amiloides/química , Ácidos Carboxílicos/farmacología , Fármacos Neuroprotectores/farmacología , Ácido Oleanólico/análogos & derivados , Ácido Oleanólico/farmacología , Fragmentos de Péptidos/química , Antraquinonas/química , Antraquinonas/farmacología , Ácidos Carboxílicos/química , Línea Celular Tumoral , Humanos , Lisina/química , Fármacos Neuroprotectores/química , Ácido Oleanólico/química , Triterpenos Pentacíclicos/química , Triterpenos Pentacíclicos/farmacología , Multimerización de Proteína , Triterpenos/química , Triterpenos/farmacologíaRESUMEN
Oligomers of the 42-mer amyloid-ß protein (Aß42), rather than fibrils, cause synaptic dysfunction in the pathology of Alzheimer's disease (AD). The nucleation phase in a nucleation-dependent aggregation model of Aß42 is related to the formation of oligomers. Uncaria rhynchophylla is one component of "Yokukansan", a Kampo medicine, which is widely used for treating AD symptoms. Previously, an extract of U. rhynchophylla was found to reduce the aggregation of Aß42, but its active principles have yet to be identified. In the present work, uncarinic acid C (3) was identified as an inhibitor of Aß42 aggregation that is present in U. rhynchophylla. Moreover, compound 3 acted as a specific inhibitor of the nucleation phase of Aß42 aggregation. Compound 3 was synthesized from saponin A (10), an abundant byproduct of rutin purified from Uncaria elliptica. Comprehensive structure-activity studies on 3 suggest that both a C-27 ferulate and a C-28 carboxylic acid group are required for its inhibitory activity. These findings may aid the development of oligomer-specific inhibitors for AD therapy.